Pfizer on Wednesday asked the Food and Drug Administration for full approval for a booster dose. The company said its Phase 3 data showed that people who received a third dose between five to eight months after the second shot had antibody levels three times higher than levels seen after the second dose.

Because the Pfizer shots were approved by the FDA on Monday, Pfizer is now asking the agency to consider a "supplemental" application for boosters for people ages 16 and over. This is a "rolling submission," with Pfizer intending to complete the submission by the end of the week.

The Biden administration said its goal is to have boosters available beginning Sept. 20, with the recommendation of getting one eight months after the second shot of Pfizer or Moderna.

-ABC News' Sony Salzman

A baby under the age of 1 died in connection to COVID-19 in the last 24 hours in Louisiana, the state's Department of Health said Wednesday.

This marked Louisiana's first pediatric COVID-19 death in six months, the department said. The baby was one of 110 people in Louisiana to die of COVID-19 in the last 24 hours.

Eleven children in Louisiana have died from COVID-19 since the start of the pandemic, the department said.

There are now over 100,000 COVID-19 patients in U.S. hospitals, the most in seven months, according to federal data.

The rate of hospital admissions per capita among Americans 29 and younger is at the highest point of the pandemic, according to federal data.

Compared with July 4, six times as many children are being admitted to hospitals, and daily deaths are up 281% over the last six weeks to 775, according to federal data.

Eight states have ICUs over 90% full: Alabama (100%), Arkansas (89.58%), Florida (93.52%), Georgia (92.74%), Kentucky (89.33%), Mississippi (92.93%), Oklahoma (88.93%) and Texas (93.12%).

-ABC News' Arielle Mitropoulos

The number of New Jersey residents hospitalized with COVID-10 has climbed to more than 1,000 for the first time since May 11, Gov. Phil Murphy said Wednesday.

"We've come too far to go backward," the governor tweeted. "Get vaccinated and let's end this."

Japan has suspended the use of about 1.63 million doses of Moderna's COVID-19 vaccine due to reported contamination, as the country grapples with surging infections.

Japanese drugmaker Takeda Pharmaceutical Co., which is in charge of distributing the Moderna vaccine in Japan, said in a press release Thursday that it has received reports of foreign substances in some unused vials at multiple inoculation sites. Although some doses might have been administered, Takeda said there have been no reports of safety concerns tied to the affected vials so far.

After consulting with Japan's Ministry of Health, Labor and Wealth, Takeda said it decided as a safety precaution to stop using doses from three separate lots, manufactured in the same production line as the contaminated vials. The company said it has requested Moderna to conduct an emergency investigation into the issue.

For doses from non-suspended lots, Takeda urged people to check the vials for discolouration, foreign substances or other abnormalities before continuing to use. Meanwhile, the Japanese health ministry said it will work with Takeda to supply alternative doses in an effort to minimize the impact on the country's vaccination progress.

Moderna told ABC News that it has put the 1.63 million doses on hold in Japan after being notified that some of the vials may have been contaminated. One of the three lots received "several complaints of particulate matter" in its vials, the American drugmaker said, while the two other adjacent lots were put on hold out of "an abundance of caution" and for continued assurance of quality.

According to Moderna, the manufacturing issue may have come from one of the lines used at its contract manufacturing site in Spain. The Massachusetts-based company said it is looking into the contamination reports and "proactively communicating with Japan’s health authorities and its partners as the investigation proceeds." Moderna added that it remains "committed to working transparently and expeditiously" with its Japanese distribution partner and with regulators to address any potential concerns. No safety or efficacy concerns have been identified so far, the company said.

Moderna noted that the pause in Japan does not impact doses distributed in the United States, or put the American supply at risk in any way.